PTC Therapeutics, Inc. Operating Lease Liability
PTC Therapeutics, Inc. (PTCT) had Operating Lease Liability of $106.07 million as of 2025-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Balance Sheet › Liabilities
us-gaap:OperatingLeaseLiability · last filed 2026-02-19
- 2025-12-31: Operating Lease, Liability $106.07M.
- 2025-09-30: Operating Lease, Liability $107.30M.
- 2025-06-30: Operating Lease, Liability $82.96M.
- 2025-03-31: Operating Lease, Liability $85.02M.
| Period end | Operating Lease, Liability |
|---|---|
| 2025-12-31 | $106.07M 10-K · filed 2026-02-19 |
| 2025-09-30 | $107.30M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $82.96M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $85.02M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $85.31M 10-K · filed 2025-02-27 |
| 2024-09-30 | $96.88M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $92.83M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $119.41M 10-Q · filed 2024-04-25 |
| 2023-12-31 | $110.63M 10-K · filed 2024-02-29 |
| 2023-09-30 | $111.39M 10-Q · filed 2023-10-26 |
| 2023-06-30 | $110.62M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $110.04M 10-Q · filed 2023-04-27 |
| 2022-12-31 | $110.23M 10-K · filed 2023-02-21 |
| 2022-09-30 | $111.02M 10-Q · filed 2022-10-27 |
| 2022-06-30 | $146.25M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $79.80M 10-Q · filed 2022-05-03 |
| 2021-12-31 | $80.89M 10-K · filed 2022-02-22 |
| 2021-09-30 | $81.97M 10-Q · filed 2021-10-28 |
| 2021-06-30 | $83.76M 10-Q · filed 2021-07-29 |
| 2021-03-31 | $85.20M 10-Q · filed 2021-05-04 |
| 2020-12-31 | $86.96M 10-Q · filed 2021-10-28 |
| 2020-09-30 | $87.53M 10-Q · filed 2020-10-29 |
| 2020-06-30 | $30.38M 10-Q · filed 2020-08-05 |
| 2020-03-31 | $18.23M 10-Q · filed 2020-04-30 |
| 2019-12-31 | $14.17M 10-K · filed 2021-02-25 |
| 2019-09-30 | $14.06M 10-Q · filed 2019-10-30 |
| 2019-06-30 | $10.56M 10-Q · filed 2019-08-06 |
| 2019-03-31 | $10.79M 10-Q · filed 2019-05-02 |
| 2019-01-01 | $11.30M 10-K · filed 2020-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |